EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cellid Co. Ltd (299660) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Cellid Co. Ltd KRW 873, price KRW 2,445, upside -64.3%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7299660001

CC Thin data Oct 3, 2026

Cellid Co. Ltd

299660 · KQ

Weakest SetupStrongly overvalued and low quality.

Low debt
Mixed Growth (revenue 3y +164.1 %/yr in KRW)
Fair value 873.12 KRW · Strongly overvalued (−64.3%)
Quality 26/100
Loss-making · -136.5% net margin (FY2025)
Negative free cash flow
Trails peers (2/8)
Narrow moat 12/100
Thin data
⚠ Dilution
Watch Cellid Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

127,128 KRW 1,025 KRW Fair Value 873.12 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 1,025 KRW – 127,128 KRW · fair‑value band 651.58 KRW – 1,303 KRW · the 2,445 KRW price screens above the 873.12 KRW fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Cellid Co. in your weekly email

Every Wednesday you see whether Cellid Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies.

Show more

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.

Stock analysis

Cellid Co. Ltd (299660) currently trades at 2,445 KRW, while our model-based Fair Value estimate is 873.12 KRW, 64.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 651.58 KRW (bear) to 1,303 KRW (bull), the price of 2,445 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cellid Co. Ltd reported revenue of 8.8B KRW in FY2025 versus 909M KRW in FY2021, a compound +76.6%/yr. Reported net income was −12.1B KRW in FY2025.

Key figures

Market cap 72.1B KRW (≈ $53.6M) · P/S ratio 17.3 · Net margin −137% · Return on equity −26.7% · Return on assets (EBIT) −19.8% · Operating margin −768% · Revenue (TTM) 4.2B KRW · Free cash flow −35.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 139% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −64%, 299660 screens richer than that median.

Fair Value models

Bear 651.58 KRW Fair Value 873.12 KRW Bull 1,303 KRW
Price 2,445 KRW · Upside -64.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,258 KRW 1,685 KRW 2,515 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,258 KRW 1,685 KRW 2,515 KRW 54

Open the full fair value analysis →

Notify me when 299660 reaches fair value

Put 299660 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 26/100

Of which business quality 26 · Market factors (momentum, volatility) 28

Profitability 1
Margins and returns on capital today
Quality Growth 84
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 8
Calm price path (market factor)
Momentum 45
Price trend over the last 3–12 months (market factor)
52W Momentum 22
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 23/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+112.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+164.1%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,431.2% (2021) → −128.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

299660 screens overvalued: fair value 64% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Cellid Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 608 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −64.3% · Below median
Profitability
Return on assets −10.7% · Below median
Net margin (TTM) −136.5% · Bottom 25%
Growth and dividend
Revenue growth 0.0% · Above median
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.01× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)91 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cellid Co. Ltd · Fair Value
873.12 KRW −64%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cellid Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/299660

Frequently asked questions

Is Cellid Co. Ltd (299660) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 873.12 KRW versus a price of 2,445 KRW, about −64% upside (overvalued).
What is the fair value of 299660?
Our model-based fair value for Cellid Co. Ltd is 873.12 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 2,445 KRW.
What is the quality score of 299660?
Cellid Co. Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cellid Co. Ltd (299660)?
Our model-based price target is the fair value of 873.12 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 651.58 KRW, optimistic scenario 1,303 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Cellid Co. Ltd stock forecast for 2026?
Our models put fair value at 873.12 KRW, about −64% upside versus a price of 2,445 KRW (overvalued). Cautious scenario 651.58 KRW, optimistic scenario 1,303 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Cellid Co. Ltd (299660)?
Cellid Co. Ltd reported trailing-twelve-month revenue of about 4.2B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Cellid Co. Ltd (299660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cellid Co. Ltd it is 873.12 KRW per share (as of Oct 3, 2026), against a price of 2,445 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cellid Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 299660 trades above its calculated fair value: price 2,445 KRW, fair value 873.12 KRW, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 299660?
No. The price is what the market pays today (2,445 KRW); the fair value is what the company's own numbers justify (873.12 KRW). For Cellid Co. Ltd the two are 1,572 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Cellid Co. Ltd worth?
The market values Cellid Co. Ltd at about 72.1B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 2,445 KRW; our models calculate a fair value of 873.12 KRW per share.
What do the bullish and bearish scenarios say about 299660?
Our models span a range for Cellid Co. Ltd: cautious scenario 651.58 KRW, base 873.12 KRW, optimistic 1,303 KRW per share (as of Oct 3, 2026, price 2,445 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cellid Co. Ltd (299660)?
Balance-sheet figures for Cellid Co. Ltd (as of Oct 3, 2026): return on equity −26.7%, debt of 0.18 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 299660 from its 52-week high?
Cellid Co. Ltd trades at 2,445 KRW, about 41% below its 52-week high of 4,110 KRW and 139% above the low of 1,025 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 873.12 KRW is for.
Which stocks are comparable to Cellid Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cellid Co. Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 2,445 KRW, calculated fair value 873.12 KRW (−64%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 299660 calculated?
We run Cellid Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 873.12 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Cellid Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cellid Co. Ltd (299660)?
The closing price on Oct 2, 2026 was 2,445 KRW. Our model-based fair value is 873.12 KRW, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cellid Co. Ltd right now?
The price sits above even our optimistic bull case (1,303 KRW). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (651.58 KRW to 1,303 KRW) leaves room in how you read the outcome.

Key figures of Cellid Co. Ltd

How large is the market capitalisation of Cellid Co. Ltd (299660)?
The market capitalisation of Cellid Co. Ltd is 72.1B KRW (≈ $53.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cellid Co. Ltd (299660)?
The price-to-sales ratio of Cellid Co. Ltd is 17.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Cellid Co. Ltd (299660)?
The net margin of Cellid Co. Ltd is −137% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cellid Co. Ltd (299660)?
The return on equity (ROE) of Cellid Co. Ltd is −26.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cellid Co. Ltd (299660)?
On an EBIT basis the return on assets of Cellid Co. Ltd is −19.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cellid Co. Ltd (299660)?
The operating margin of Cellid Co. Ltd is −768% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Cellid Co. Ltd (299660) generate?
The free cash flow of Cellid Co. Ltd is −35.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cellid Co. Ltd (299660) carry?
The net debt of Cellid Co. Ltd is 5.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cellid Co. Ltd in the live analysis

One click puts Cellid Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.